Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 9 studies | 40% ± 26% | |
oligodendrocyte | 9 studies | 23% ± 7% | |
oligodendrocyte precursor cell | 8 studies | 26% ± 10% | |
astrocyte | 8 studies | 30% ± 12% | |
retinal ganglion cell | 7 studies | 50% ± 22% | |
interneuron | 6 studies | 38% ± 21% | |
epithelial cell | 6 studies | 24% ± 9% | |
adipocyte | 6 studies | 22% ± 8% | |
GABAergic neuron | 6 studies | 47% ± 20% | |
neuron | 5 studies | 28% ± 10% | |
endothelial cell | 5 studies | 28% ± 14% | |
hepatocyte | 4 studies | 46% ± 15% | |
GABAergic interneuron | 3 studies | 24% ± 8% | |
microglial cell | 3 studies | 20% ± 5% | |
amacrine cell | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 98% | 1432.09 | 2599 / 2642 | 99% | 11.10 | 701 / 705 |
liver | 100% | 3950.74 | 226 / 226 | 92% | 18.81 | 373 / 406 |
adrenal gland | 100% | 2089.79 | 257 / 258 | 91% | 12.03 | 210 / 230 |
kidney | 98% | 696.10 | 87 / 89 | 90% | 8.04 | 808 / 901 |
skin | 100% | 3059.01 | 1806 / 1809 | 83% | 9.41 | 391 / 472 |
bladder | 86% | 842.90 | 18 / 21 | 96% | 18.96 | 486 / 504 |
esophagus | 86% | 1326.38 | 1246 / 1445 | 95% | 14.57 | 173 / 183 |
lung | 94% | 775.53 | 543 / 578 | 82% | 10.63 | 948 / 1155 |
stomach | 78% | 1046.74 | 280 / 359 | 97% | 13.59 | 278 / 286 |
intestine | 74% | 1110.28 | 713 / 966 | 98% | 15.76 | 517 / 527 |
uterus | 82% | 503.51 | 139 / 170 | 85% | 10.04 | 390 / 459 |
breast | 73% | 1448.49 | 334 / 459 | 91% | 11.35 | 1022 / 1118 |
prostate | 77% | 359.42 | 188 / 245 | 85% | 7.09 | 426 / 502 |
ovary | 57% | 257.73 | 102 / 180 | 97% | 12.58 | 418 / 430 |
thymus | 56% | 356.15 | 366 / 653 | 72% | 4.51 | 434 / 605 |
pancreas | 19% | 130.84 | 61 / 328 | 94% | 12.05 | 168 / 178 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.26 | 1 / 1 |
adipose | 85% | 1634.53 | 1024 / 1204 | 0% | 0 | 0 / 0 |
spleen | 82% | 387.26 | 198 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 6.77 | 36 / 45 |
eye | 0% | 0 | 0 / 0 | 68% | 4.94 | 54 / 80 |
blood vessel | 44% | 322.30 | 587 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 33% | 342.01 | 302 / 929 | 0% | 0 | 0 / 0 |
heart | 26% | 190.40 | 225 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 21% | 1.51 | 6 / 29 |
muscle | 8% | 61.20 | 62 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042759 | Biological process | long-chain fatty acid biosynthetic process |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0034626 | Biological process | fatty acid elongation, polyunsaturated fatty acid |
GO_0019367 | Biological process | fatty acid elongation, saturated fatty acid |
GO_0034625 | Biological process | fatty acid elongation, monounsaturated fatty acid |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
GO_0006636 | Biological process | unsaturated fatty acid biosynthetic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0009923 | Cellular component | fatty acid elongase complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005515 | Molecular function | protein binding |
GO_0009922 | Molecular function | fatty acid elongase activity |
Gene name | ELOVL6 |
Protein name | Very long chain fatty acid elongase 6 (EC 2.3.1.199) (3-keto acyl-CoA synthase ELOVL6) (ELOVL fatty acid elongase 6) (ELOVL FA elongase 6) (Elongation of very long chain fatty acids protein 6) (Fatty acid elongase 2) (hELO2) (Fatty acyl-CoA elongase) (Long-chain fatty-acyl elongase) (Very long chain 3-ketoacyl-CoA synthase 6) (Very long chain 3-oxoacyl-CoA synthase 6) Elongation of very long chain fatty acids protein (EC 2.3.1.199) (Very-long-chain 3-oxoacyl-CoA synthase) |
Synonyms | FACE LCE |
Description | FUNCTION: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that elongates fatty acids with 12, 14 and 16 carbons with higher activity toward C16:0 acyl-CoAs. Catalyzes the synthesis of unsaturated C16 long chain fatty acids and, to a lesser extent, C18:0 and those with low desaturation degree. May participate in the production of saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . |
Accessions | ENST00000394607.7 Q9H5J4 D6RCU0 ENST00000302274.8 ENST00000514184.5 D6RBP4 ENST00000506625.5 D6RHI2 ENST00000503885.1 |